Global Dermatophytic Onychomycosis Market 2016-2020


◆タイトル:Global Dermatophytic Onychomycosis Market 2016-2020
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Dermatophytic Onychomycosis

Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.

Technavio’s analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Dermatophytic Onychomycosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Anacor Pharmaceuticals
• Galderma
• Janssen Biotech
• Novartis
• Valeant Pharmaceuticals

[Other prominent vendors]
• Abeona Therapeutics
• Allergan
• Elorac
• GlaxoSmithKline
• Hexima
• Hisamitsu Pharmaceutical
• Mayne Pharma
• MediQuest Therapeutics
• Meiji Seika Pharma
• Merz Pharma
• Moberg Pharma
• NanoBio
• NovaBiotics
• Nuvo Research
• Pfizer
• Polichem
• Promius Pharma
• Sanofi
• Seren Pharmaceuticals
• Taro Pharmaceutical
• Topica Pharmaceuticals
• Viamet Pharmaceuticals

[Market driver]
• Increase in R&D
• For a full, detailed list, view our report

[Market challenge]
• Adverse effects and limited efficacy of drugs
• For a full, detailed list, view our report

[Market trend]
• Increased focus on combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Product offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Overview: Dermatophytic onychomycosis
• Types of dermatophytic onychomycosis
• Risk factors
• Management
• Epidemiology

PART 06: Pipeline analysis
• TDT 067
• P-3058
• MOB-015
• VT-1161
• Luliconazole solution, 10%
• ME1111
• NP213
• HXP124

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by route of administration
• Topical
• Oral

PART 09: Geographical segmentation
• Global dermatophytic onychomycosis market by geographical segmentation 2015-2020
• Dermatophytic onychomycosis market in Americas
• Dermatophytic onychomycosis market in EMEA
• Dermatophytic onychomycosis market in APAC

PART 10: Market drivers
• Increase in R&D
• Growing prevalence of dermatophytic onychomycosis
• Unmet medical needs
• Rise in prevalence of diabetes

PART 11: Impact of drivers

PART 12: Market challenges
• Adverse effects and limited efficacy of drugs
• Lack of awareness
• Increased availability of generics and alternative therapies
• Product recalls by US FDA

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Increased focus on combination therapies
• Outsourcing of drugs manufacturing
• Increase in strategic alliances among vendors
• Incorporation of novel technology for product development

PART 15: Vendor landscape
• Competitive scenario
• Anacor Pharmaceuticals
• Galderma
• Janssen Biotech
• Novartis
• Valeant Pharmaceuticals
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Key buying criteria for dermatophytic onychomycosis drugs
Exhibit 02: Percentage of population undergoing treatment globally 2015
Exhibit 03: Pharmacological treatment for dermatophytic onychomycosis
Exhibit 04: Treatment algorithm for dermatophytic onychomycosis
Exhibit 05: Global dermatophytic onychomycosis therapeutics market overview
Exhibit 06: Global dermatophytic onychomycosis market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Comparison of activity of topical medications for onychomycosis
Exhibit 09: Comparison of activity of oral medications for onychomycosis
Exhibit 10: Global dermatophytic onychomycosis market segmentation by route of administration based on volume 2015
Exhibit 11: Dermatophytic onychomycosis market in US by route of administration based on revenue 2015
Exhibit 12: Segmentation of global dermatophytic onychomycosis market based on geography 2015
Exhibit 13: Global dermatophytic onychomycosis market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Dermatophytic onychomycosis market in Americas 2015-2020 ($ billions)
Exhibit 15: Dermatophytic onychomycosis market in EMEA 2015-2020 ($ billions)
Exhibit 16: Dermatophytic onychomycosis market in APAC 2015-2020 ($ billions)
Exhibit 17: Global dermatophytic onychomycosis market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Comparison of onychomycosis prevalence with major diseases in US 2013
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: Anacor Pharmaceuticals: Key takeaways
Exhibit 22: Galderma: Key takeaways
Exhibit 23: Janssen Biotech: Key takeaways
Exhibit 24: Novartis: Key takeaways
Exhibit 25: Valeant Pharmaceuticals: Key takeaways


Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals.





★調査レポート[皮膚糸状菌爪真菌症治療薬の世界市場2016-2020] (Global Dermatophytic Onychomycosis Market 2016-2020 / IRTNTR8747)販売に関する免責事項
[皮膚糸状菌爪真菌症治療薬の世界市場2016-2020] (Global Dermatophytic Onychomycosis Market 2016-2020 / IRTNTR8747)についてEメールでお問い合わせ